Supernus Pharmaceuticals (SUPN) Change in Receivables (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Change in Receivables of $29.5 million for Q2 2026, up 712.89% year-over-year from $3.6 million in Q2 2025, and up 624.54% on a QoQ basis from -$5.6 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Change in Receivables (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Change in Receivables for 16 years, with the latest figure at $29.5 million in Q2 2026.
- Change in Receivables for Q2 2026 came in at $29.5 million, up 712.89% year-over-year; the trailing twelve-month figure through Jun 2026 was $47.4 million (up 506.46% YoY), and the FY2025 annual result was $22.3 million, up 1173.34% from the prior year.
- Change in Receivables rose to $29.5 million in Q2 2026, from -$5.6 million in the prior quarter.
- Over five years, Change in Receivables peaked at $29.5 million in Q2 2026 and troughed at -$22.0 million in Q1 2023.
- A 5-year average of $2.3 million and a median of $3.0 million in 2023 frame the typical range for Change in Receivables.
- The widest annual swing landed in 2023, when Change in Receivables plunged 476.36%; it then jumped 712.89% in 2026.
- A 5-year view of Change in Receivables shows it stood at $1.4 million in 2022, then jumped by 69.74% to $2.4 million in 2023, then sank by 239.37% to -$3.3 million in 2024, then surged by 592.92% to $16.4 million in 2025, then surged by 79.51% to $29.5 million in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were $29.5 million in Q2 2026, -$5.6 million in Q1 2026, and $16.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn | 29.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.47 Mn |
| Jun 30, 2026 | 29.47 Mn |
| Mar 31, 2026 | -5.62 Mn |
| Mar 31, 2026 | -5.62 Mn |
| Dec 31, 2025 | 16.42 Mn |
| Dec 31, 2025 | 16.42 Mn |
| Sep 30, 2025 | 7.13 Mn |
| Sep 30, 2025 | 7.13 Mn |
| Jun 30, 2025 | -4.81 Mn |
| Jun 30, 2025 | -4.81 Mn |
| Mar 31, 2025 | 3.56 Mn |
| Mar 31, 2025 | 3.56 Mn |
| Dec 31, 2024 | -3.33 Mn |
| Dec 31, 2024 | -3.33 Mn |
| Sep 30, 2024 | -7.09 Mn |
| Sep 30, 2024 | -7.09 Mn |
| Jun 30, 2024 | 4.76 Mn |
| Jun 30, 2024 | 4.76 Mn |
| Mar 31, 2024 | 3.58 Mn |
| Mar 31, 2024 | 3.58 Mn |